Formosa and Rxilient sign licensing agreement for APP13007
The agreement includes upfront payments, sales and regulatory milestones.
Drug Development
FDA approves Eli Lilly’s Jaypirca in relapsed or refractory CLL/SLL
AGC Biologics to expand cell line development with ATUM partnership
Citizen Health and UCB collaborate for epilepsy drug development
Solid Biosciences’ SGT-212 gains FDA rare paediatric disease status
Lotus submits NDA for VIZZ in South Korea to treat presbyopia
Eisai seeks PMDA approval for subcutaneous Leqembi in Japan
US FDA approves Lupin’s Armlupeg injection
